This is how Bern­stein divvies up a $40B Covid-19 vac­cine mar­ket among the lead­ers in the race to an ap­proval

The fren­zied race to reg­u­la­to­ry ap­provals this year is com­ing down to the fin­ish line. The win­ners can im­me­di­ate­ly piv­ot to the com­pe­ti­tion for the mega-block­buster rev­enue gains to come as the start­ing gun is fired for the glob­al race to seize mar­ket share.

Pfiz­er $PFE and their de­vel­op­ment part­ners at BioN­Tech have seized a clear — though small — lead in the race to win FDA ap­proval for the first Covid-19 vac­cine. And the an­a­lyst team work­ing with Bern­stein’s Ron­ny Gal says the phar­ma gi­ant al­so has the mus­cle to seize a clear ad­van­tage in win­ning the biggest slice of the $40 bil­lion mar­ket that lies in wait for the lead­ing play­ers next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.